Cellevolve Bio, Inc.

None  Welcome to this week's Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word—or the bad—from your shop to Max Bayer or Gabrielle Masson, and we will feature it here at the end of each week.  Longtime BioMarin CEO hands baton off to Genentech chief BioMarin In pharma executive leadership terms, 18 years is an eternity. For comparison, that’s longer than the entire tenure of Robert Bradway at Amgen, who himself is a pharmaceutical staple.  But such was the length of Jean-Jacques Bienaimé’s tenure at the helm of BioMarin. Still, all good things must come to an end, and Bienaimé is hanging it up. The rare disease drug developer is not looking far for a replacement. Taking over will be Genentech CEO Alexander Hardy, from a company headquartered just a few miles south of BioMarin’s Marin County campus. BioMarin says the announcement followed a “multi-year succession planning process.” Hardy takes over a company that in the years since Bienaimé’s appointment has grown to about 3,000 employees and three commercial products. BioMarin recently reported $581.3 million in third-quarter earnings, a 15% increase compared to the same period a year ago.  Genentech will, for now, stick with interim CEO Ashley Magargee, who leads the U.S. commercial portfolio. She’s been temporarily guiding the company since Hardy’s “recent sabbatical.” Fierce Pharma  J&J’s cancer R&D chief to retire  Johnson & Johnson J&J’s oncology R&D team is transitioning from the leadership of Peter Lebowitz, M.D., Ph.D., to Yusri Elsayed, M.D., Ph.D., effective Jan. 1, 2024. The healthcare giant said Lebowitz will retire after a “remarkable career” that included overseeing a group that delivered 14 novel medicines.  He oversaw work on therapies such as small molecules, advanced biologics, cell therapies, vaccine platforms, translational research, diagnostics and immuno-oncology therapies. Lebowitz’s efforts also helped J&J secure dozens of deals in key indications.  Elsayed, meanwhile, will rise from his role as vice president and head of the hematologic malignancies group at J&J. He has worked at the company for more than 18 years. Prior to J&J, he briefly worked at Bristol Myers Squibb. Release Viridian taps ex-Magenta CFO for chief executive job  Viridian Therapeutics  Magenta Therapeutics had a tough go of it after the death of a patient in a clinical trial halted the study and ultimately spurred the closure of the entire company. Now, one executive of the company has found a new landing spot.  Stephen Mahoney, Magenta’s former chief financial and operating officer, has been named the CEO of Viridian Therapeutics and a member of the board. Before Magenta, Mahoney was the president and chief operating officer of Kiniksa Pharmaceuticals and led commercial work for Synageva Biopharma Corp.  Mahoney’s hiring comes after previous CEO Scott Myers officially departed on the company Oct. 29. In addition to Mahoney’s arrival, the company unveiled a couple of new FcRn inhibitors and announced a $185 million private placement. Release > Dren Bio has tapped Amit Mehta, Ph.D., to serve as the company’s chief operating officer and chief business officer. Mehta joins after an 18-year run at Roche’s Genentech, where he was most recently VP and head of business development. Release > Vir Biotechnology has chosen Jennifer Towne, Ph.D., to serve as EVP and chief scientific officer starting Nov. 6. Towne joins Vir from Johnson & Johnson’s Janssen pharmaceutical arm, where she most recently held the role of SVP, immunology discovery and external innovation. Release > Third Harmonic Bio’s chief scientific officer Adrian Ray, Ph.D., has transitioned to the role of scientific adviser, while Chief Financial Officer Robert Ho is set to exit the company Nov. 10. The inflammatory-disease-focused biotech has initiated a search for their successors. Release > Amarin has appointed Jonathan Provoost to serve as EVP, chief legal and compliance officer starting Nov. 15. He most recently served as Tris Pharma’s VP, general counsel and chief compliance officer and has past experience at Mallinckrodt Pharmaceuticals' Ikaria, Kos Pharmaceuticals and Bristol Myers Squibb. Release > Lexicon is bringing on Matthew Cullen to serve as VP of value and access as well as Lisa DeFrancesco to serve as head of investor relations and corporate strategy. Before Lexicon, Cullen was VP of value, access and policy at Apellis Pharmaceuticals, while DeFrancesco most recently served as SVP of investor relations and corporate affairs for Amarin Pharma. Release > Medicenna Therapeutics is reducing its U.S. presence with Chief Financial Officer Jeff Caravella and Chief Business Officer Brent Meadows departing the company. Medicenna will now seek a CFO who is familiar with the Toronto Stock Exchange. Fierce Biotech > RS BioTherapeutics has promoted Michelle Shuffett, M.D., to serve as chief medical officer. Shuffett joined the company in May as SVP of medical and scientific affairs and has previous experience at Boehringer Ingelheim. Release > Sangamo Therapeutics is laying off 162 employees—equivalent to 40% of its U.S. workforce. As part of the restructuring, Chief Operating Officer D. Mark McClung and Chief Scientific Officer Jason Fontenot, Ph.D., will both be heading for the exit. Fierce Biotech > Cell therapy biotech cTRL Therapeutics has chosen Derrell Porter, M.D., to helm the company. Porter most recently served as founder and CEO of Cellevolve Bio and has held past roles at Atara Bio, Gilead Sciences, AbbVie, Amgen and McKinsey & Company. Release > Ocuphire Pharma is welcoming George Magrath, M.D., aboard as CEO. Magrath most recently led Lexitas Pharmaceutical Services through its acquisition by QHP Capital. Release > Storm Therapeutics has selected Marguerite Hutchinson to serve as the biotech’s chief business officer. Hutchinson was previously the chief operating officer and general counsel fo Daiichi Sankyo’s Plexxikon. Release > Myriad Genetics has chosen Sam Raha as chief operating officer, effective Dec. 11. Raha has previously served as Agilent’s president of diagnostics and genomics group and Illumina’s VP of global marketing. Release > Gate Bioscience has exited stealth with $60 million in hand and a roster of leaders onboard, including: Jordi Mata-Fink, Ph.D., co-founder and CEO; Pat Sharp, Ph.D., scientific co-founder and VP of discovery science; Raman Talwar, co-founder and chief technology officer; and Brian Cathers, Ph.D., chief scientific officer. Release > Seattle-based ProfoundBio is adding a couple of key hires to its executive team, naming Erin Lavelle as chief operating officer and chief financial officer and Kevin Hambly as chief business officer. Lori Kunkel, M.D., has also been tapped to lead the company's scientific advisory board. Release > 4DMT has called on Alan Cohen, M.D., to be the therapeutic head of the pulmonary division. One of his most recent roles was as SVP and chief medical officer of gene editing biotech Metagenomi. Release > RNA biotech Senisca is swapping executive positions, with former Chief Operating Officer Sarah Cole, Ph.D., now taking on the role of CEO, while former CEO Kirsty Semple assumes the role of COO. Semple served as launch CEO since January 2020, while Cole joined Senisca in March 2023. Release > Endeavor BioMedicines has elected Paul Frohna, M.D., Ph.D., to serve as its chief medical officer. Frohna joins from ImCheck Therapeutics, where he was CMO and head of R&D, and has held past roles at Bioniz Therapeutics, Receptos, ProFibrix, Fibrogen and Roche’s Genentech. Release > Cognito Therapeutics has chosen Christian Howell as chief commercial officer. Howell joins the neurotech company from Aetion’s medical device and diagnostic group, where he was SVP and general manager. Release > Spatial multi-omics developer Stellaromics has appointed Todd Dickinson as president and CEO. Dickinson previously held technical and commercial executive roles at Illumina and Bionano Genomics and most recently served as CEO of Cantata Bio. Fierce Medtech

INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease, completed enrollment in February 2023 Topline data expected in the third quarter of 2023 Cash, cash equivalents and marketable securities of $193.4 million as of Dec. 31, 2022 expected to be sufficient to support clinical and operational goals through 2025 Company to host conference call and webcast today at 8:00 a.m. ET CHARLOTTESVILLE, Va. and CARMEL, Ind., March 27, 2023 (GLOBE NEWSWIRE) --Acumen Pharmaceuticals Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) and is designed for the treatment of Alzheimer’s disease (AD), today reported financial results for the full year ended December 31, 2022 and provided a business update. “2022 was a year of significant accomplishment as we advanced the clinical development of ACU193, our novel therapeutic targeting toxic amyloid beta oligomers for the treatment of Alzheimer’s Disease. We recently completed enrollment in our Phase I INTERCEPT-AD trial and are encouraged by preliminary pharmacokinetic and safety data that support ACU193’s differentiated product profile,” said Daniel O’Connell, President and Chief Executive Officer of Acumen. “We believe that our continued execution will drive Acumen’s momentum during 2023. Our Phase 1 topline results expected in the third quarter and anticipated interaction with FDA in the fourth quarter of 2023 will help inform our next phase of clinical development. With cash runway expected through 2025, a strong scientific foundation, and an increasingly attractive market environment, we believe we are well positioned to achieve our near-term milestones and to advance our mission of delivering a novel treatment option for patients with Alzheimer’s Disease.” Recent Business Highlights and Anticipated Milestones ACU193 Clinical Development In October 2022, Fast Track designation was granted by the U.S. Food and Drug Administration (FDA) for ACU193 for the treatment of early Alzheimer’s disease. Fast Track designation is granted to drugs being developed for the treatment of serious or life-threatening conditions where there is an unmet medical need. Fast Track designation does not change the standard for approval, but a drug candidate that receives Fast Track designation is eligible for more frequent communication with the FDA throughout the drug development process for the purpose of expediting the drug's development, review, and potential approval. In January 2023, a protocol amendment was submitted to the FDA with respect to Cohort 7 of the Company’s Phase 1 INTERCEPT-AD clinical trial to reduce the dose to 25 mg/kg every two weeks (updated from 60 mg/kg every two weeks). The change was based in part on a blinded review of preliminary pharmacokinetic data in the trial, inclusive of levels of ACU193 in plasma and cerebrospinal fluid, which indicated a dose of 60 mg/kg every two weeks should not be needed to attain central target engagement, and preliminary safety data, including two asymptomatic cases of ARIA-E (one in Cohort 4 after a single 60 mg/kg dose and one in Cohort 5 after the third 10 mg/kg dose). In February 2023, enrollment was completed in the Company’s Phase 1 INTERCEPT-AD trial of ACU193 in patients with early Alzheimer’s disease. Acumen anticipates reporting topline results from this trial, including safety and proof-of-mechanism data, in the third quarter of 2023. Corporate In 2022, we continued to expand our team with talent necessary to advance our mission to develop a novel treatment for AD. These appointments included Liean Schenck, MS as our VP, Head of Chemistry, Manufacturing and Controls (CMC) and Derek Meisner, JD as our Chief Legal Officer. In January 2023, Derrell Porter, M.D. joined Acumen’s Board of Directors. Dr. Porter is a physician-entrepreneur with more than 20 years of experience in drug development. He is currently the Founder and CEO of Cellevolve, a development and commercialization company focused on cell therapy, and previously served in commercial and corporate development roles at Atara Biotherapeutics, Inc., Gilead, AbbVie and Amgen. 2022 Financial Results Cash Balance. As of December 31, 2022, cash, cash equivalents and marketable securities totaled $193.4 million, compared to cash, cash equivalents and marketable securities of $225.9 million as of December 31, 2021. The decrease in cash is related to funding ongoing operations. Research and Development (R&D) Expenses. R&D expenses for 2022 were $32.4 million compared to $12.3 million in 2021. The increase in R&D expenses in 2022 compared to 2021 was primarily due to increased costs related to our ongoing clinical trial, which was initiated in 2021 and started enrolling patients in the second half of 2021, as well as nonclinical research and development activity. General and Administrative (G&A) Expenses. G&A expenses for 2022 were $12.9 million, compared to $7.3 million in 2021. The increase in G&A expenses in 2022 compared to 2021 was primarily due to increased expenses as a public company and additions to its financial and administrative infrastructure, such as costs related to personnel, accounting, marketing, recruiting and travel and entertainment expenses. Loss from Operations. Losses from operations for 2022 were $45.2 million, compared with $19.6 million in 2021. This increase was due to the increased R&D and G&A expenses over the prior year period. Net Loss. Net loss for the year ended December 31, 2022 was $42.9 million, compared to a net loss of $100.6 million for the year ended December 31, 2021. Net loss in 2021 includes a $81.2 million non-cash expense that represents the changes in fair value of Acumen’s Series B tranche liability and Series A-1 warrant liability. Conference Call Details Acumen will host a conference call and live audio webcast today, March 27, 2023, at 8:00 a.m. ET. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance. The webcast audio will be available via this link. An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at . About ACU193 ACU193 is a recombinant humanized immunoglobin gamma 2 (IgG2) monoclonal antibody (mAb) discovered and developed based on its selectivity for soluble AβOs, which Acumen believes are the most toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques. Soluble AβOs have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration. By selectively targeting toxic soluble AβOs, ACU193 aims to directly address what a growing body of evidence indicates is a primary underlying cause of the neurodegenerative process in AD. ACU193 has been granted Fast Track designation for the treatment of early Alzheimer’s disease by the U.S. Food and Drug Administration. About INTERCEPT-AD INTERCEPT-AD is a Phase 1, U.S.-based, multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and tolerability, and establishing clinical proof of mechanism, of ACU193 in patients with early Alzheimer’s disease (AD). Sixty-five individuals with early AD (mild cognitive impairment or mild dementia due to AD) enrolled in this first-in-human study of ACU193. The INTERCEPT-AD study consists of single-ascending-dose (SAD) and multiple-ascending-dose (MAD) cohorts and is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and target engagement of intravenous doses of ACU193. The study has completed enrollment across multiple investigative sites located in the United States. More information can be found on , NCT identifier NCT04931459. About Acumen Pharmaceuticals, Inc. Acumen, headquartered in Charlottesville, VA, with clinical operations based in Carmel, IN, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are primary triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, ACU193, a humanized monoclonal antibody that selectively targets toxic soluble AβOs in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer’s disease patients. For more information, visit . Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as “believes,” “expects,” “anticipates,” “could,” “should,” “would,” “seeks,” “aims,” “plans,” “potential,” “will,” “milestone” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning Acumen’s business and continued momentum, Acumen’s ability to achieve its strategic and financial goals, including its projected use of cash, cash equivalents and marketable securities and the sufficiency of its cash resources through 2025, and the therapeutic potential of Acumen’s product candidate, ACU193, including the anticipated timeline for reporting topline safety and proof-of-mechanism data and results, ACU193’sits differentiated product profile, as supported by preliminary pharmacokinetic and safety data, as compared to other monoclonal antibodies in development, and the potential benefits and outcomes of receiving Fast Track designation from and anticipated upcoming interactions with the FDA. These statements are based upon the current beliefs and expectations of Acumen management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of the COVID-19 pandemic, geopolitical events and macroeconomic conditions, such as rising inflation and interest rates, supply disruptions and uncertainty of credit and financial markets. These and other risks concerning Acumen’s programs are described in additional detail in Acumen’s filings with the Securities and Exchange Commission (“SEC”), including in Acumen’s most recent Annual Report on Form 10-K, and in subsequent filings with the SEC. Copies of these and other documents are available from Acumen. Additional information will be made available in other filings that Acumen makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Acumen expressly disclaims any obligation to update or revise any forward-looking statement, except as otherwise required by law, whether, as a result of new information, future events or otherwise. Investors: Alex Braun abraun@acumenpharm.com Media: AcumenPR@westwicke.com Acumen Pharmaceuticals, Inc. Balance Sheets (in thousands, except share and per share data) December 31, 2022 December 31, 2021 ASSETS Current assets Cash and cash equivalents $ 130,101 $ 122,162 Marketable securities, short-term 47,504 72,075 Prepaid expenses and other current assets 2,724 4,424 Total current assets 180,329 198,661 Marketable securities, long-term 15,837 31,619 Property and equipment, net 165 36 Right-of-use asset 105 - Other assets 151 14 Total assets $ 196,587 $ 230,330 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 1,640 $ 1,088 Accrued clinical trial expenses 2,717 147 Accrued expenses and other current liabilities 3,350 3,912 Operating lease liability, current portion 105 - Total current liabilities 7,812 5,147 Total liabilities 7,812 5,147 Commitments and contingencies Stockholders' equity Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of December 31, 2022 and 2021 - - Common stock, $0.0001 par value; 300,000,000 shares authorized and 41,025,062 and 40,473,270 shares issued and outstanding as of December 31, 2022 and 2021, respectively 4 4 Additional paid-in capital 359,949 352,981 Accumulated deficit (170,427 ) (127,571 ) Accumulated other comprehensive loss (751 ) (231 ) Total stockholders' equity 188,775 225,183 Total liabilities and stockholders' equity $ 196,587 $ 230,330 Statements of Operations and Comprehensive Loss (in thousands, except share and per share data) Year Ended December 31, 2022 2021 Operating expenses Research and development $ 32,361 $ 12,305 General and administrative 12,876 7,279 Total operating expenses 45,237 19,584 Loss from operations (45,237 ) (19,584 ) Other income (expense) Interest income, net 2,392 84 Other income (expense), net (11 ) 51 Change in fair value of preferred stock tranche rights liability and preferred stock warrant liability - (81,157 ) Total other income (expense) 2,381 (81,022 ) Net loss (42,856 ) (100,606 ) Other comprehensive loss Unrealized loss on marketable securities (520 ) (231 ) Comprehensive loss $ (43,376 ) $ (100,837 ) Net loss per common share, basic and diluted $ (1.06 ) $ (5.02 ) Weighted-average shares outstanding, basic and diluted 40,601,936 20,057,534 Statements of Cash Flows (in thousands) Year Ended December 31, 2022 2021 Cash flows from operating activities Net loss $ (42,856 ) $ (100,606 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation 32 4 Change in fair value of preferred stock tranche rights liability and preferred stock warrant liability - 81,157 Stock-based compensation expense 3,061 922 Amortization of premiums and accretion of discounts on marketable securities, net 487 155 Amortization of right-of-use asset 137 - Other non-cash expense - 109 Changes in operating assets and liabilities: Prepaid expenses and other current assets 1,700 (3,881 ) Other assets (137 ) (14 ) Accounts payable 552 557 Accrued clinical trial expenses 2,570 147 Operating lease liability (137 ) - Accrued expenses and other current liabilities (562 ) 3,489 Net cash used in operating activities (35,153 ) (17,961 ) Cash flows from investing activities Purchases of marketable securities (41,514 ) (104,080 ) Proceeds from maturities and sales of marketable securities 80,860 - Purchases of property and equipment (161 ) (40 ) Net cash provided by (used in) investing activities 39,185 (104,120 ) Cash flows from financing activities Proceeds from issuance of common stock, net of issuance costs 3,792 168,556 Proceeds from exercise of stock options 115 15 Proceeds from issuance of Series B milestone shares, net of issuance costs - 30,031 Proceeds from exercise of Series A-1 warrant - 1,250 Proceeds from exercise of common stock warrants - 614 Net cash provided by financing activities 3,907 200,466 Net change in cash and cash equivalents 7,939 78,385 Cash and cash equivalents at the beginning of the period 122,162 43,777 Cash and cash equivalents at the end of the period $ 130,101 $ 122,162

CHARLOTTESVILLE, Va. and CARMEL, Ind., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today announced Derrell Porter, M.D., has joined its Board of Directors. “We are thrilled to welcome Dr. Porter to our Board of Directors at a time when we’re rapidly advancing clinical development of ACU193,” said Daniel O’Connell, President and Chief Executive Officer of Acumen Pharmaceuticals. “Dr. Porter brings significant expertise in drug development and commercialization to the Board as we develop a novel and potentially disease-modifying treatment for Alzheimer’s disease. His deep experience in diseases that benefit from personalized treatments and combination therapies will be invaluable to Acumen.” Dr. Porter said: “This is an exciting time for drug development in Alzheimer’s disease, and I am drawn to Acumen’s pioneering science and the therapeutic promise of ACU193. I look forward to contributing my experience bringing meaningful treatments to market as Acumen works to deliver therapies that can substantially impact those affected by this devastating disease.” Dr. Porter is a physician-entrepreneur with more than 20 years of experience in drug development. He is currently the Founder and CEO of Cellevolve, a development and commercialization cell therapy biotech focused on neglected diseases, and previously served in commercial and corporate development roles at Atara Bio, Gilead, AbbVie and Amgen. He is also a Board Member at Passage Bio, a genetics medicine company developing therapeutics for disorders of the central nervous system; Portal Innovations, LLC, a venture development engine which delivers seed capital, specialized equipment, lab space, and management expertise to early-stage biotech companies; and an Advisory Committee Member at the University of Pennsylvania School of Medicine. Dr. Porter started his career at McKinsey & Company. He earned his M.D. from the Perelman School of Medicine and MBA from the Wharton School at the University of Pennsylvania, and his B.S. in Neuroscience from the University of California, Los Angeles. About ACU193 ACU193 is a humanized monoclonal antibody (mAb) discovered and developed based on its selectivity for soluble AβOs, which Acumen believes are the most toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques. Soluble AβOs have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration. By selectively targeting toxic soluble AβOs, ACU193 aims to directly address what a growing body of evidence indicates is a primary underlying cause of the neurodegenerative process in AD. ACU193 has been granted Fast Track designation for the treatment of early Alzheimer’s disease by the U.S. Food and Drug Administration. About Acumen Pharmaceuticals, Inc. Acumen, headquartered in Charlottesville, VA, with clinical operations based in Carmel, IN, is a clinical stage biopharmaceutical company developing a novel disease-modifying approach to treat Alzheimer’s disease. Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are primary triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, ACU193, a humanized monoclonal antibody that selectively targets toxic soluble AβOs in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer’s disease patients. For more information, visit www.acumenpharm.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as “believes,” “expects,” “anticipates,” “could,” “should,” “would,” “seeks,” “aims,” “plans,” “potential,” “will,” “milestone” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include the those concerning the therapeutic potential of Acumen’s product candidate, ACU193. These statements are based upon the current beliefs and expectations of Acumen management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of the COVID-19 pandemic, geopolitical events and macroeconomic conditions, such as rising inflation and interest rates, supply disruptions and uncertainty of credit and financial markets. These and other risks concerning Acumen’s programs are described in additional detail in Acumen’s filings with the Securities and Exchange Commission (“SEC”), including in Acumen’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, and future filings with the SEC, including Acumen’s Quarterly Report on Form 10-Q for the quarter ended and September 30, 2022. Copies of these and other documents are available from Acumen. Additional information will be made available in other filings that Acumen makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Acumen expressly disclaims any obligation to update or revise any forward-looking statement, except as otherwise required by law, whether, as a result of new information, future events or otherwise. Investors:Alex Braunabraun@acumenpharm.com Media:AcumenPR@westwicke.com